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Abstract: Tapentadol, a Schedule II opioid with a combination of µ-opioid activity and norepineph-
rine reuptake inhibition, is used for the management of moderate to severe acute and chronic pain.
Its dual mechanism of action is thought to reduce opioid-related side effects that can complicate pain
management. Since approval, tapentadol has been tracked across multiple outcomes suggesting abuse
liability, and a pattern of relatively low, although not absent, abuse liability has been found. This
retrospective cohort study further details the abuse liability of tapentadol as an active pharmaceu-
tical ingredient (API) when immediate-release as well as extended-release formulations were on the
market together (fourth quarter of 2011 to second quarter of 2016). Tapentadol (API) was compared
with tramadol, hydrocodone, morphine, oxycodone, hydromorphone, and oxymorphone across Poison
Center, Drug Diversion, and Treatment Center Programs Combined data streams from the Re-
searched Abuse, Diversion and Addiction-Related Surveillance system. Findings suggest the public
health burden related to tapentadol to date is low, but present. Event rates of abuse per population-
level denominators were significantly lower than all other opioids examined. However, when adjusted
for drug availability, event rates of abuse were lower than most Schedule II opioids studied, but were
not the lowest. Disentangling these 2 sets of findings further by examining various opioid formu-
lations, such as extended-release and the role of abuse-deterrent formulations, is warranted.
Perspective: This article presents the results from an examination of tapentadol API across the Re-
searched Abuse, Diversion and Addiction-Related Surveillance System: a broad and carefully designed
postmarketing mosaic. Data to date from Poison Center, Drug Diversion, and Treatment Centers com-
bined suggest a low, but present public health burden related to tapentadol.
© Published by Elsevier Inc. on behalf of the American Pain Society
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Tapentadol is a Schedule II centrally acting analge-sic consisting of a combination of µ-opioid activityand norepinephrine reuptake inhibition, which is
thought to enhance moderate to severe acute and chronic
pain relief with fewer opioid-related side effects.30,31
Tapentadol immediate-release (IR; Nucynta; Depomed,
Newark, CA) was approved by the U.S. Food and Drug
Administration (FDA) in December 2008 and the extended-
release (ER) formulation (Nucynta ER; Depomed) was
approved by the FDA in August 2011. Tapentadol ER is
formulated with an Intac (Grünenthal, Aachen, Germany)
crush-resistant matrix.17
Since its approval, tapentadol IR has been tracked across
multiple outcomes suggestive as potential signals of abuse
liability. Between the third quarter of 2009 and the second
quarter of 2011, Researched Abuse, Diversion and
Addiction-Related Surveillance (RADARS) System Poison
Center Program data revealed that intentional expo-
sures to tapentadol were minimal (.003 to .02 cases per
100,000 population). A low public health effect of
tapentadol intentional exposure was inferred from the
per population-level outcome.11
However, when examined as rate per 1,000 unique recipi-
ents of dispensed drug, rates of intentional exposures of
tapentadol hovered around .30 per 1,000 unique recipients
of dispensed drug, which were similar to oxycodone, higher
than hydrocodone, and lower than tramadol. At the same
time, data gathered from RADARS System Treatment Center
Programs Combined indicated rates of tapentadol IR abuse
were low but variable (remaining close to 0 per 100,000
population).11 Rates of tapentadol IR nonmedical use in
college students were also reported to be low (.7%).10
This set of findings was interpreted as being driven by
varying degrees of market penetration of tapentadol IR
across different geographic regions and experimenta-
tion with this newly available opioid.11
Subsequent postmarketing studies investigating abuse
of tapentadol IR as well as ER formulations reported low
relative risk of past month abuse of tapentadol (an ag-
gregate of IR + ER) between the first quarter of 2011 and
the third quarter of 2012 in substance abusers seeking
treatment.3 However, when IR and ER formulations were
examined separately, the relative risk of tapentadol IR
abuse did not differ from that of fentanyl IR. Further, the
relative risk of tapentadol ER abuse did not differ from
that of hydromorphone ER, suggesting a degree of abuse
liability in both,3 although messages posted by recre-
ational drug users during the same time period revealed
low levels of interest in tapentadol (ER + IR).24 Although
message posting in itself may not be a reliable source of
abuse liability, it can be considered to provide a signal
or insight into agents that may, or in the case of tapentadol,
may not be particularly sought after for nonmedical use.
Meanwhile, studies of drug diversion, identified as cases
opened by drug diversion investigators in the United States
between the third quarter of 2009 and the third quar-
ter of 2014,12,13 the price paid for illicitly obtained
tapentadol,15 or the number of cases that were submit-
ted to the National Forensic Laboratory Information
System33 have generally reported low or nonexistent levels
of illicit buying or selling of tapentadol.
To date, a pattern of relatively low, although not
absent, abuse liability of ER and IR tapentadol has been
documented. As a multimodal opioid, tapentadol is a
new and unique molecule, but little has been written
about its abuse liability as an entity, either with behav-
ioral pharmacology models29 or within the postmarketing
framework.4-7 As such, the purpose of this study was to
investigate the abuse liability of tapentadol as an active
pharmaceutical ingredient (API) during the time that IR
as well as ER were on the market together (fourth
quarter of 2011 through the second quarter of 2016) to
determine whether the abuse liability of tapentadol as
an API remains one of the lowest of scheduled opioid
compounds. Tapentadol API refers to any mention of
tapentadol (ER, IR, or formulation not known).
Methods
Data Sources
The RADARS System Programs
These analyses use data from the RADARS System,
which provides postmarketing surveillance data regard-
ing prescription medication abuse, misuse, and diversion
to various stakeholders including regulatory agencies,
policy-making organizations, and pharmaceutical com-
panies. The RADARS System is comprised of a mosaic of
programs that gather data from several unique popu-
lations along the spectrum of drug abuse. Rates of abuse
and diversion of tapentadol-containing products were
compared with products containing oxycodone,
hydrocodone, oxymorphone, hydromorphone, mor-
phine, and tramadol.
Comparators were chosen on the basis of their sched-
uling, market share, and use characteristics. Tapentadol
is a Schedule II opioid, and most comparators were also
Schedule II. Oxycodone and hydrocodone were chosen
as references because they are widely prescribed,
oxymorphone and hydromorphone were chosen as com-
parators because they have market shares similar to
tapentadol (internal IMS Health data) and morphine
was chosen because it is a standard reference drug. In
addition, the Schedule IV opioid tramadol was selected
because it is a low potency, mixed-action opioid.
The RADARS System Poison Center Program obtains
data from individuals within the general population and
from health care providers who are seeking advice re-
garding potential toxic exposures, including exposures
to prescription opioids and stimulants. For the calcula-
tion of rates, an event is defined as a mention of a
product within a drug group by exposures identified as
intentional abuse cases. Intentional abuse cases are ex-
posures “resulting from the intentional improper or
incorrect use of a substance where the patient was likely
attempting to gain a high, euphoric effect or some other
psychotropic effect, including recreational use of a sub-
stance for any effect.”25 The Poison Center Program
detects product-specific prescription drug abuse and
misuse in near real-time. Poison Center data associate
strongly with other measures of national prescription
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opioid exposures, such as emergency department visits16
and national vital statistics,14 as well as with clinician
ratings of intentional abuse.28 As of the second quarter
2016, the Poison Center Program collected data from 50
of 55 regional U.S. Poison Centers covering 48 states, in-
cluding urban, suburban, and rural regions. In the second
quarter of 2016, 91% of poison centers participated in
the program and 94% of the U.S. population resided in
areas covered by these centers. Investigators at each par-
ticipating poison center collect data using a nationally
standardized electronic health record. In addition to the
institutional review board (IRB) approvals from each par-
ticipating regional poison center, this study protocol was
granted exempt status by the Colorado Multiple IRB.
The RADARS System Drug Diversion Program con-
ducts a quarterly survey of law enforcement investigators
on the diversion of prescription opioid and stimulant prod-
ucts in their jurisdictions. Diversion officers represent
municipal police departments, multijurisdictional drug task
forces, county sheriffs’ departments, regulatory agen-
cies such as state medical and pharmacy boards, state
police agencies, prosecutors’ offices, and departments of
health. Drug diversion officers submit data on the number
of new documented drug diversion cases within their ju-
risdiction for specific prescription products of interest.
Although formal comparative analyses have not been con-
ducted, similar patterns of diversion are observed within
the RADARS mosaic20 between RADARS and National Fo-
rensic Laboratory Information System estimates,32,33 and
have been noted between RADARS diversion findings and
other national surveys.21
In the second quarter of 2016, the Drug Diversion
Program collected data from 205 of 250 participating
agencies in 48 states (all states except Hawaii; this is a
response rate of approximately 82% of participating agen-
cies). Approximately 38% of the population falls with the
coverage area. Coverage is most complete in the mid-
Atlantic and Plains states, with New England and
California also having substantial coverage (maps avail-
able in the Dart et al., 2015 supplement12). For the
calculation of rates, an event represents the number of
newly opened written complaints or reports involving
products within the drug group of interest. The Drug Di-
version Program study protocol was deemed to be
nonhuman subject research by Nova Southeastern Uni-
versity’s IRB.
The RADARS System Treatment Center Programs Com-
bined is comprised of the Opioid Treatment Program as
well as the Survey of Key Informants’ Patients Program.
Each newly admitted patient is offered the opportunity
to complete a standardized self-administered question-
naire that solicits information on specific prescription and
illegal opioid products abused in the past month. Both
programs use a common core questionnaire allowing data
to be combined. For the calculation of rates, an event
is an endorsement of past month use to get high with
a product within the drug group of interest. Treatment
Centers Combined data have strong associations with the
national Treatment Episodes Data Set.23
In the second quarter of 2016, 59 of 74 participating
methadone maintenance treatment programs provided
at least 1 survey to the Opioid Treatment Program. The
59 centers are in 30 states. Respondents are primarily from
the coasts and in the mid-Atlantic states.12 The Opioid
Treatment Program study protocol was reviewed and ap-
proved by the IRB of the National Development and
Research Institutes, Inc.
As of the second quarter of 2016, The Survey of Key
Informants’ Patients Program involved 129 substance
abuse treatment programs in 46 states, representing ap-
proximately 48% of the U.S. population. Approximately
78% of the patients who are asked complete a valid
version of the survey, and they receive modest compen-
sation for doing so. Survey of Key Informants’ Patients
data include representation from urban, suburban, and
rural centers, with coverage being fairly consistent across
the lower 48 states, excluding Montana, which does not
currently have any representation, whereas California,
Nevada, Utah, Texas, Wisconsin, and South Carolina having
lighter than average coverage. The Survey of Key Infor-
mants’ Patients Program study protocol was reviewed and
approved by Washington University, St. Louis IRB.
Denominators
Three denominators were used in the present analy-
ses: population, total number of prescriptions dispensed,
and total number of dosage units dispensed.
Population estimates were calculated by assuming linear
growth between 2000 and 2010 U.S. census and was ex-
trapolated using this same rate of change from October
1, 2011 to June 30, 2016. For any given year quarter, the
total population covered by the RADARS System pro-
grams is computed in this manner and this number is used
as the denominator when calculating population rates.
QuintilesIMS Government Solutions, Inc, a subsidiary
of QuintilesIMS Health Inc (Atlanta, GA) obtains product
and geographically specific data from a sample of ap-
proximately 50% of retail pharmacies in the United States
(SDI database, generated by QuintilesIMS Government
Solutions, Inc). QuintilesIMS Health uses a complex pro-
prietary projection methodology to extrapolate from the
observed data to the universe of all retail prescriptions
in the United States. The study uses national estimates
from QuintilesIMS Health for total prescriptions dis-
pensed and total dosage units dispensed at the 3-digit
ZIP code level for products of interest. For any given
quarter, the total of prescriptions and the total of dosage
units in the 3-digit ZIP codes covered by the RADARS
System Programs were used as the denominators when
calculating drug utilization rates.
Data Analysis
Plots of quarterly abuse and diversion rates were gen-
erated for descriptive purposes. Event rates are calculated
by dividing the sum of events from October 2011 through
June 2016 by the sum of the population or prescrip-
tions dispensed or drug units dispensed within the 3-digit
ZIP codes covered by a particular program in a given
quarter. Rates therefore reflect a quarterly average where
quarters with larger denominators have greater influence
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on the overall average. Population rates are scaled per
1,000,000 individuals, whereas drug utilization rates are
scaled per 10,000 prescriptions dispensed and per 100,000
dosage units dispensed. Confidence intervals (CIs) for the
cumulative analyses are calculated using the exact Poisson
method. Rate ratios compare the cumulative rate of abuse
or diversion for each opioid to that of tapentadol and
are calculated using a saturated Poisson regression. The
natural log of each denominator enters the model as an
offset variable to calculate rates. Rate ratios are de-
picted on the logarithmic scale to account for the wide
range of values among comparator products. Rate ratios
>1 indicate the comparator product is abused or di-
verted more than tapentadol whereas ratios <1 indicate
the comparator product is abused or diverted less than
tapentadol. Comparator product rate ratios with 95% CIs
that cross 1 do not differ from tapentadol, and com-
parator products with overlapping 95% CIs do not differ
from each other.
Results
Poison Center Program
Rate Per 1,000,000 Population
From October 2011 through June 2016 there were 87
mentions of tapentadol products by intentional abuse ex-
posure cases reported to participating poison centers.
Fig 1A presents the Poison Center Rate of Intentional
Abuse per 1,000,000 population according to quarter.
Rates of tapentadol intentional abuse were the lowest
among all products and ranged from .007 to .036 during
this period.
Average quarterly rate (event rate) of intentional abuse
of tapentadol per 1,000,000 population was .015 (95%
CI = .012–.019; Table 1, top section). Event rates of in-
tentional abuse were greatest for oxycodone (1.302, 95%
CI = 1.272–1.332), followed by hydrocodone (1.255, 95%
CI = 1.226–1.284), tramadol (.521, 95% CI, .502–.540), mor-
phine (.275, 95% CI, .262–.289), hydromorphone (.137,
95% CI, .127–.147), and oxymorphone (.114, 95% CI, .106–
.124). Rate ratios per 1,000,000 population of intentional
abuse calculated between tapentadol and comparators
revealed that comparators were intentionally abused from
7.414 times (oxymorphone) to 84.322 times (oxycodone)
the rate of intentional abuse of tapentadol at the popu-
lation level (Table 1, top section; Fig 2A).
Rate Per 10,000 Prescriptions Dispensed
Fig 1B presents the Poison Center rate of intentional
abuse per 10,000 prescriptions dispensed according to
quarter. Rates of tapentadol intentional abuse ranged
from .088 to .453 during this period. Average quarterly
rate (event rate) of intentional abuse of tapentadol per
10,000 prescriptions dispensed was .207 (95% CI = .166–
.255), which was neither the largest nor smallest event
rate (Table 1, middle section). Event rates of inten-
tional abuse were greatest for oxymorphone (1.168, 95%
CI, 1.079–1.261) and lowest for hydrocodone (.131, 95%
CI, .128–.134). Rate ratios of intentional abuse per 10,000
Table 1. Poison Center: Rates of Intentional Abuse per 1,000,000 Population, Rate Ratios and 95%
CIs for Tapentadol API and Comparators
DRUG (API)
EVENT RATE LOWER 95% CI UPPER 95% CI RATE RATIO LOWER95% CI UPPER 95% CI
RATES AND RATE RATIOS OF INTENTIONAL ABUSE PER 1,000,000 POPULATION, 95% CIS
Tapentadol API .015 .012 .019 1
Oxymorphone API .114 .106 .124 7.414 5.927 9.274
Hydromorphone API .137 .127 .147 8.851 7.091 11.047
Morphine API .275 .262 .289 17.816 14.356 22.110
Tramadol API .521 .502 .540 33.736 27.258 41.753
Hydrocodone API 1.255 1.226 1.284 81.276 65.788 100.411
Oxycodone API 1.302 1.272 1.332 84.322 68.256 104.169
RATES AND RATE RATIOS OF INTENTIONAL ABUSE PER 10,000 PRESCRIPTIONS DISPENSED, 95% CIS
Hydrocodone API .131 .128 .134 .632 .512 .781
Tramadol API .159 .153 .165 .769 .622 .952
Tapentadol API .207 .166 .255 1
Oxycodone API .280 .274 .287 1.356 1.098 1.675
Morphine API .374 .356 .393 1.811 1.459 2.248
Hydromorphone API .534 .497 .573 2.584 2.071 3.226
Oxymorphone API 1.168 1.079 1.261 5.651 4.517 7.069
RATES AND RATE RATIOS OF INTENTIONAL ABUSE PER 100,000 DOSAGE UNITS DISPENSED, 95% CIS
Hydrocodone API .020 .019 .020 .703 .569 .868
Tramadol API .022 .021 .022 .766 .619 .947
Tapentadol API .028 .023 .035 1
Oxycodone API .036 .035 .037 1.275 1.032 1.575
Morphine API .052 .050 .055 1.862 1.500 2.310
Hydromorphone API .062 .057 .066 2.184 1.750 2.726
Oxymorphone API .166 .153 .179 5.886 4.705 7.362
NOTE. Data are organized by rate of intentional abuse. Also see Fig 1.
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Figure 1. Poison Center: intentional abuse. Quarterly rates of tapentadol and comparator opioid intentional abuse per 1,000,000
population (A), per 10,000 prescriptions dispensed (B), and per 100,000 dosing units dispensed (C) from the fourth quarter (Q) of
2011 to the second Q of 2016.
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Figure 2. Poison Center: intentional abuse. Rate ratios of tapentadol and comparator opioid intentional abuse per 1,000,000 popu-
lation (A), per 10,000 prescriptions dispensed (B), and per 100,000 dosing units dispensed (C) from fourth quarter (Q) of 2011 to
the second Q of 2016. Tapentadol is the comparator and represented by the vertical line at 1.
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prescriptions dispensed calculated between tapentadol
and comparators revealed that hydrocodone and tramadol
were intentionally abused less than tapentadol (.632 and
.769 times the rate of tapentadol intentional abuse),
whereas the remainder of comparators were abused from
1.356 (oxycodone) to 5.651 (oxymorphone) times the rate
of intentional abuse of tapentadol (Table 1, middle
section; Fig 2B).
Rate Per 100,000 Dosage Units Dispensed
Fig 1C presents the Poison Center rate of intentional
abuse per 100,000 dosing units dispensed according to
quarter. Rates of tapentadol intentional abuse ranged
from .012 to .066 during this period. Average quarterly
rate (event rate) of intentional abuse of tapentadol per
100,000 dosing units dispensed was .028 (95% CI, .023–
.035) which was neither the largest nor smallest event
rate of intentional abuse (Table 1, bottom section). Event
rates were greatest for oxymorphone (.166, 95% CI, .153–
.179), and lowest for hydrocodone (.020, 95% CI, .019–
.020). Rate ratios of intentional abuse per 100,000
prescriptions dispensed calculated between tapentadol
and comparators revealed that hydrocodone and tramadol
were intentionally abused less than tapentadol (.703 and
.766 times the rate of tapentadol abuse), whereas the
remainder of comparators were abused from 1.275
(oxycodone) to 5.886 (oxymorphone) times the rate of
intentional abuse of tapentadol (Table 1, bottom section;
Fig 2C).
Drug Diversion
Rate Per 1,000,000 Population
From October 2011 through June 2016 there were 58
reports of tapentadol diversion. Fig 3A presents the rates
of drug diversion per 1,000,000 population according to
quarter. Rates of tapentadol diversion were the lowest
among all products and ranged from .000 to .070 during
this period.
Average quarterly rate (event rate) of diversion was
.029 (95% CI = 022–.038) for tapentadol (Table 2, top
section). Drug diversion rates were greatest for oxycodone
(9.234, 95% CI = 9.101–9.368) and hydrocodone (7.656,
95% CI = 7.535–7.779). Rate ratios reveal that compara-
tors were diverted from 23.172 (oxymorphone) to 316.862
(oxycodone) times the rate of tapentadol diversion per
1,000,000 population (Table 2, top section; Fig 4A).
Rate Per 10,000 Prescriptions Dispensed
Fig 3B presents the rates of drug diversion per 10,000
prescriptions dispensed according to quarter. Rates of
tapentadol diversion were similar to tramadol and ranged
from .000 to .794 during this period. Average quarterly
rates (event rates) of diversion per 10,000 prescriptions
dispensed were lowest for tapentadol and tramadol (.334
and .335, 95% event rate CIs overlap; Table 2, middle
section). Drug diversion rates were greatest for
oxymorphone (6.183, 95% CI = 5.856–6.522) and
hydromorphone (5.427, 95% CI = 5.221–5.638). Rate ratios
reveal that comparators significantly different from
tapentadol were diverted from 2.613 (hydrocodone) to
18.507 (oxymorphone) times the rate of tapentadol di-
version per 10,000 prescriptions dispensed (Table 2, middle
section; Fig 4B).
Rate Per 100,000 Dosage Units Dispensed
Fig 3C presents the rates of drug diversion per 100,000
dosing units dispensed according to quarter. Rates of
tapentadol diversion were similar to tramadol and ranged
from .000 to .1027 during this period. Average quar-
terly rates (event rates) of diversion per 100,000 dosage
units dispensed were lowest for tapentadol and tramadol
(.045 and .047, respectively; 95% event rate CIs overlap;
Table 2, bottom section). Drug diversion rates were great-
est for oxymorphone (.860, 95% CI = .814–.907) and
hydromorphone (.620, 95% CI = .596–.644). Rate ratios
reveal that comparators significantly different from
tapentadol were diverted from 2.957 (hydrocodone) to
19.308 (oxymorphone) times the rate of tapentadol di-
version per 100,000 dosage units dispensed (Table 2,
bottom section; Fig 4C).
Treatment Center Programs Combined
Rate Per 1,000,000 Population
From October 2011 through June 2016 there were 744
endorsements of past month use to get high with
tapentadol products. Fig 5A presents the Treatment Center
Programs Combined rates of past-month use to get high
per 1,000,000 population according to quarter. Rates of
past month use of tapentadol to get high were the lowest
among all products and ranged from .115 to .472 during
this period.
Average quarterly rate (event rate) of reported use for
getting high within the past month with tapentadol per
1,000,000 population was the lowest rate during the study
period (.245, 95% CI = .228–.263; Table 3, top section).
Rate of reported use for getting high in the past month
was greatest for oxycodone (12.969; 95% CI = 12.841–
13.097) and hydrocodone (10.102, 95% CI = 9.989–
10.216). Rate ratios reveal that comparator use for getting
high in the past month ranged from 3.475 (tramadol) to
52.972 (oxycodone) times the rate of tapentadol use per
1,000,000 population (Table 3, top section; Fig 6A).
Rate Per 10,000 Prescriptions Dispensed
Fig 5B presents the rates of past month use of
tapentadol to get high per 10,000 prescriptions dis-
pensed by quarter. Rates of tapentadol use to get high
ranged from 1.584 to 6.065 during this period. Average
quarterly rates (event rates) of reported use for getting
high within the past month with tapentadol per 10,000
prescriptions dispensed was 3.162 (95% CI = 2.939–
3.398), which was neither the largest nor smallest event
rate (Table 3, middle section). Rate of reported use for
getting high in the past month was greatest for
oxymorphone (29.450, 95% CI = 28.881–30.027) and
hydromorphone (21.240, 95% CI = 20.924–21.559) and
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Figure 3. Drug Diversion. Quarterly rates of tapentadol and comparator opioid drug diversion per 1,000,000 population (A), per
10,000 prescriptions dispensed (B), and per 100,000 dosing units dispensed (C), from the fourth quarter (Q) of 2011 to the second
Q of 2016.
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lowest for tramadol (.264, 95% CI = .254–.274). Rate ratios
reveal that comparator use for getting high in the
past month ranged from .083 (tramadol) to 9.313
(oxymorphone) times the rate of tapentadol use (Table 3,
middle section; Fig 6B).
Rate Per 100,000 Dosage Units Dispensed
Fig 5C presents the rates of past month use of
tapentadol to get high per 100,000 dosing units dis-
pensed according to quarter. Rates of tapentadol use to
get high ranged from .219 to .823 during this period.
Average quarterly rate (event rate) of reported use for
getting high within the past month with tapentadol per
100,000 dosing units dispensed was .436 (95% CI = .405–
.468), which was neither the largest nor smallest event
rate (Table 3, bottom section). Rate of reported use for
getting high in the past month was greatest for
oxymorphone (4.221, 95% CI = 4.140–4.304) and
hydromorphone (2.471, 95% CI = 2.434–2.508) and lowest
for tramadol (.036, 95% CI = .034–.037). Rate ratios reveal
that comparator use for getting high in the past month
ranged from .082 (tramadol) to 9.686 (oxymorphone)
times the rate of tapentadol use (Table 3, bottom section;
Fig 6C).
Discussion
The purpose of this report was to evaluate the abuse
liability of the tapentadol API from October 2011 through
June 2016. When evaluated per 1,000,000 population
across Poison Center, Drug Diversion, and Treatment
Center Programs Combined data streams, tapentadol was
the least-mentioned API, with rates being <.5 cases per
1,000,000 population across all data streams during this
time period. These data suggest a low overall public
health burden associated with abuse or diversion of
tapentadol.
When adjusted for drug utilization (ie, per 10,000 pre-
scriptions dispensed and per 100,000 dosage units
dispensed), tapentadol abuse liability was generally low
compared with other opioids, but present, nonetheless.
Reports varied according to data stream.
Evaluation of Drug Diversion data revealed that rates
of tapentadol diversion did not differ from those of
tramadol, both of which had the lowest rates of drug
diversion among all comparators. Tramadol, scheduled
as a Schedule IV opioid with pharmacology including
µ-receptor agonism and norepinephrine and serotonin
reuptake inhibition,26 is recognized for low to modest
abuse liability and relatively low levels of abuse and
diversion.9,35,37 It is possible that the low diversion rate
of tapentadol across all denominators is because
tapentadol is less likely to be accessed through the illicit
markets that are usually attended to by law enforce-
ment and more likely to be diverted through other
distribution systems, however, this remains to be deter-
mined. Low rates of tapentadol diversion have also been
supported in existing literature6,11,13,24 suggesting that to
date, this is a stable finding.
Table 2. Drug Diversion. Rates of Diversion per 1,000,000 Population, Rate Ratios, and 95% CIs
for Tapentadol API and Comparators
DRUG (API)
EVENT RATE LOWER 95% CI UPPER 95% CI RATE RATIO LOWER 95% CI UPPER 95% CI
RATES AND RATE RATIOS OF DRUG DIVERSION PER 1,000,000 POPULATION, 95% CIS
Tapentadol API .029 .022 .038 1
Oxymorphone API .675 .640 .712 23.172 17.816 30.139
Tramadol API 1.034 .990 1.080 35.483 27.333 46.063
Morphine API 1.284 1.234 1.334 44.052 33.957 57.147
Hydromorphone API 1.322 1.272 1.373 45.362 34.970 58.842
Hydrocodone API 7.656 7.535 7.779 262.724 203.011 340.001
Oxycodone API 9.234 9.101 9.368 316.862 244.864 410.029
RATES AND RATE RATIOS OF DRUG DIVERSION PER 10,000 PRESCRIPTIONS DISPENSED, 95% CIS
Tapentadol API .334 .254 .432 1
Tramadol API .350 .335 .365 1.047 .806 1.359
Hydrocodone API .873 .859 .887 2.613 2.019 3.381
Morphine API 1.974 1.898 2.052 5.908 4.554 7.664
Oxycodone API 2.119 2.089 2.150 6.343 4.902 8.208
Hydromorphone API 5.427 5.221 5.638 16.243 12.522 21.070
Oxymorphone API 6.183 5.856 6.522 18.507 14.229 24.070
RATES AND RATE RATIOS OF DRUG DIVERSION PER 100,000 DOSAGE UNITS DISPENSED, 95% CIS
Tapentadol API .045 .034 .058 1
Tramadol API .047 .045 .050 1.064 .820 1.382
Hydrocodone API .132 .130 .134 2.957 2.285 3.826
Oxycodone API .272 .269 .276 6.118 4.728 7.917
Morphine API .274 .264 .285 6.163 4.750 7.994
Hydromorphone API .620 .596 .644 13.918 10.729 18.053
Oxymorphone API .860 .814 .907 19.308 14.845 25.112
NOTE. Data are organized according to rate of diversion. Also see Fig 2.
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Evaluation of Treatment Center Programs Combined
and Poison Center data when adjusted for drug utiliza-
tion revealed similar patterns between the 2 data
streams. Tapentadol had neither the highest nor lowest
reported rates of use to get high in the past month
(Treatment Center Programs Combined) or intentional
abuse (Poison Center). Across both data sets, rates of
tapentadol abuse were greater than tramadol and
Figure 4. Drug Diversion. Rate ratios of tapentadol and comparator opioid drug diversion per 1,000,000 population (A), per 10,000
prescriptions dispensed (B), and per 100,000 dosing units dispensed (C) from the fourth quarter (Q) of 2011 to the second Q of
2016. Tapentadol is the comparator and represented by the vertical line at 1.
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Figure 5. Treatment Center Programs Combined: past month use to get high. Quarterly rates of tapentadol and comparator opioid
past month use to get high per 1,000,000 population (A), per 10,000 prescriptions dispensed (B), and per 100,000 dosing units
dispensed (C) from the fourth quarter (Q) of 2011 to the second Q of 2016.
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hydrocodone, with a more pronounced difference in the
Treatment Center Programs Combined. In particular, when
adjusting for drug utilization and interpreting the lon-
gitudinal data presentation, recent Treatment Center
Programs Combined data suggest a slight increase in use
of tapentadol to get high.
This finding is surprising because, similar to tramadol,
when adjusted for drug availability, hydrocodone has
been reported to have a relatively low abuse liability.1,11,27
The difference in relative rates may be a function of
formulation, namely, much of the hydrocodone API in
the present analysis consists of immediate release com-
bination hydrocodone/acetaminophen products, which
for most of the time period studied were Schedule III
substances; hydrocodone products without acetamino-
phen including Zohydro (Zogenix Inc., Emeryville, CA)
and Hysingla (Purdue Pharma, Stamford, CT) were
approved by the FDA in 2013 and 2014, respectively.18
Acetaminophen-containing products have resulted in
adverse health outcomes that are thought to deter illicit
use,18,36 although the effectiveness of this strategy can
be debated.22 Regardless, a better understanding of this
finding can be obtained by investigating these drugs as
a function of their formulation (ER vs IR).
Rates of oxycodone abuse were also found to be sig-
nificantly lower than tapentadol when adjusted for drug
utilization in the Treatment Center Programs Com-
bined data stream. This likely reflects, in part, the high
proportion of combination oxycodone/acetaminophen
products and to some extent the introduction of the abuse
deterrent formulation of ER OxyContin (Purdue Pharma)
which occurred in 2010.2,27 In addition to early studies that
revealed drug abusers generally characterized the product
as less desirable than the original OxyContin (Purdue
Pharma),34 postmarketing studies have identified general
decreases in the use as well as prescription of OxyContin
(Purdue Pharma).8,19
However, this interpretation is not intended to mini-
mize the appearance of recent increases in the rates of
past month use of tapentadol to get high in the Treat-
ment Center Programs Combined data, but rather to
provide context. The absolute numbers of past month use
to get high of tapentadol are much lower than other com-
parators by at least a factor of 10, suggesting less stable
estimates of magnitude, and indeed, as depicted in the
longitudinal data, tapentadol has had a variable pattern
of abuse. The drug changed sponsors in April 2015/
second quarter of 2015 and recent increases in use to get
high can be traced to that quarter. A similar pattern was
observed in 2011 (after the introduction of the ER for-
mulation) before levels of past month use to get high
decreased to low levels similar to tramadol. Thus, these
data warrant continued observation.
Although the RADARS data streams represent a broad
and carefully designed surveillance system, the present
findings must also be considered together with existing
limitations. The Poison Center Program relies on spon-
taneous reports, therefore, the number of cases is under-
reported and drug identification may be inaccurate. Not
all parts of the United States have prescription drug
Table 3. Treatment Center Programs Combined. Rates of Past-month Use to Get High per
1,000,000 Population, Rate Ratios and 95% CIs for Tapentadol API and Comparators
DRUG (API)
EVENT RATE LOWER 95% CI UPPER 95% CI RATE RATIO LOWER 95% CI UPPER 95% CI
RATES AND RATE RATIOS OF PAST-MONTH USE TO GET HIGH PER 1,000,000 POPULATION, 95% CIS
Tapentadol API .245 .228 .263 1
Tramadol API .851 .818 .884 3.475 3.202 3.770
Oxymorphone API 3.355 3.290 3.420 13.702 12.719 14.760
Hydromorphone API 5.675 5.590 5.760 23.179 21.539 24.944
Morphine API 5.743 5.658 5.829 23.458 21.799 25.244
Hydrocodone API 10.102 9.989 10.216 41.262 38.368 44.375
Oxycodone API 12.969 12.841 13.097 52.972 49.266 56.957
RATES AND RATE RATIOS OF PAST-MONTH USE TO GET HIGH PER 10,000 PRESCRIPTIONS DISPENSED, 95% CIS
Tramadol API .264 .254 .274 .083 .077 .091
Hydrocodone API 1.086 1.074 1.099 .344 .319 .369
Oxycodone API 2.621 2.596 2.647 .829 .771 .891
Tapentadol API 3.162 2.939 3.398 1
Morphine API 7.700 7.586 7.815 2.435 2.263 2.620
Hydromorphone API 21.240 20.924 21.559 6.716 6.241 7.228
Oxymorphone API 29.450 28.881 30.027 9.313 8.645 10.032
RATES AND RATE RATIOS OF PAST-MONTH USE TO GET HIGH PER 100,000 DOSAGE UNITS DISPENSED, 95% CIS
Tramadol API .036 .034 .037 .082 .076 .089
Hydrocodone API .166 .164 .168 .380 .354 .409
Oxycodone API .337 .334 .340 .773 .719 .831
Tapentadol API .436 .405 .468 1
Morphine API 1.085 1.069 1.101 2.489 2.313 2.679
Hydromorphone API 2.471 2.434 2.508 5.669 5.268 6.101
Oxymorphone API 4.221 4.140 4.304 9.686 8.991 10.434
NOTE. Data are organized according to past month rate of use. Also see Fig 3.
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diversion agencies, and thus data may also be subject to
under-reporting. Last, Treatment Center Programs Com-
bined data are also self-reported, and thus subject to
limitations associated therewith.12
Analyzing the abuse liability of an API has strengths
and weaknesses. It is a broad concept that serves as an
estimate of the effect of the molecule(s) of interest, re-
gardless of the formulation (IR/ER; abuse-deterrent
Figure 6. Treatment Center Programs Combined: past month use to get high. Rate ratios of tapentadol and comparator opioid
past month use to get high per 1,000,000 population (A), per 10,000 prescriptions dispensed (B), and per 100,000 dosing units
dispensed (C) from the fourth quarter (Q) of 2011 to the second Q of 2016. Tapentadol is the comparator and represented by the
vertical line at 1.
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formulation/no abuse-deterrent formulation) or whether
the molecule is packaged as a single entity or combina-
tion product. Although it lacks the specificity that an
analysis of any one of these individual categories might
provide, it yields relevant information about the general
exposures resultant from the compound. It also removes
potential product ascertainment bias among different for-
mulations of the API.
In summary, these data suggest that the public health
burden related to tapentadol, which occupies approxi-
mately 3% of the opioid market, is low, but present.
Conclusions
Event rates of abuse per the population-level denomi-
nator across the 3 data streams were significantly lower
than all other opioids examined in this study, including
Schedule II opioids (hydrocodone, hydromorphone,
oxycodone, oxymorphone, and morphine). However, when
adjusted for drug availability, these data also suggest that
tapentadol has the potential for abuse. Event rates of
abuse were lower than most Schedule II opioids studied,
but were not the lowest. Disentangling these 2 sets of
findings further by examination of various opioid for-
mulations, such as ER and the role of abuse-deterrent
formulations, is warranted.
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